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Abstract
Background: Maternal blood folate concentrations during pregnancy have been previously linked with DNA
methylation patterns, but this has been done predominantly through observational studies. We showed recently in
an epigenetic analysis of the first randomized controlled trial (RCT) of folic acid supplementation specifically in the
second and third trimesters (the EpiFASSTT trial) that methylation at some imprinted genes was altered in cord
blood samples in response to treatment. Here, we report on epigenome-wide screening using the Illumina EPIC
array (~ 850,000 sites) in these same samples (n = 86).
Results: The top-ranked differentially methylated promoter region (DMR) showed a gain in methylation with folic
acid (FA) and was located upstream of the imprint regulator ZFP57. Differences in methylation in cord blood
between placebo and folic acid treatment groups at this DMR were verified using pyrosequencing. The DMR also
gains methylation in maternal blood in response to FA supplementation. We also found evidence of differential
methylation at this region in an independent RCT cohort, the AFAST trial. By altering methylation at this region in
two model systems in vitro, we further demonstrated that it was associated with ZFP57 transcription levels.
Conclusions: These results strengthen the link between folic acid supplementation during later pregnancy and
epigenetic changes and identify a novel mechanism for regulation of ZFP57. This trial was registered 15 May 2013
at www.isrctn.com as ISRCTN19917787.
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Background
Folate is an essential B vitamin required for viable embry-
onic and fetal development and as an important dietary
constituent throughout life, fundamental in cellular biosyn-
thesis and DNA methylation pathways [1, 2]. Folic acid
(FA) is the oxidized, and more stable, synthetic form of fol-
ate which is exclusively found in supplements and fortified
foods [3]. Well-established evidence from randomized
controlled trials [4, 5] has led to recommendations, in place
globally, that women should consume 400 μg/d FA from
prior to conception until the end of the first trimester in
order to protect against neural tube defects (NTDs) [6, 7].
Despite the identification of a relationship between mater-
nal folate status and NTDs as early as 40 years ago, infor-
mation on the mechanism behind the benefit of FA
supplementation with respect to NTDs remains to be fully
elucidated (reviewed in [8]), as does the relationship of FA,
NTDs, and DNA methylation [9]. There is however little
dispute in regards to the protective effect of folic acid sup-
plementation before and in early pregnancy, which was
proven in clinical trials to reduce NTDs by approximately
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70% [10]. Furthermore, there remains a lack of evidence as
to whether it is beneficial to mother and/or child to con-
tinue this supplementation throughout the entire preg-
nancy [11, 12]. FA supplementation during pregnancy has
been associated with health benefits such as reduced risk of
low birth weight [13], language delay [14], autism [15] and
reduced risk of psychosis and other pediatric problems [16,
17]. In addition, observational studies have indicated that
FA supplement use by mothers during pregnancy is associ-
ated with better cognitive health and brain development in
the child [14, 18, 19], possibly related to the fact that there
is a brain growth spurt at the end of the second trimester
[20, 21]. However, there may also be potential adverse ef-
fects from excess folate in later pregnancy, an aspect which
would also benefit from further exploration [12].
At a molecular level, there is some evidence in human
that epigenetic changes could be the mechanism underpin-
ning some of the effects of folate, both in the first trimester
[8] in the prevention of NTDs, and also in the second and
third trimester, as reviewed elsewhere [2]. Folate is essential
for the production of S-adenosylmethionine (SAM), which
provides the methyl group to the DNA methyltransferases
(DNMTs), which carry out DNA methylation. DNA methy-
lation is an essential means of maintaining transcriptional
silencing at many different classes of genes when it occurs
at promoter and enhancer elements, including endogenous
retroviruses, genes on the inactive X, and imprinted genes
[22] but can also facilitate transcription when occurring in
the gene body [23–25]. DNA methylation is vital for em-
bryonic survival and development, as mice carrying
mutations in the DNA methyltransferases die in utero
or shortly after birth [26, 27]. Some DNA methylation
marks are inherited from the parents in the form of dif-
ferential methylation on the paternal or maternal copy.
This includes both the canonical imprinted loci, as well
as some germline and neuronal genes [25, 28, 29], at all
of which methylation plays a direct role in controlling
transcription. Both animal and human studies have in-
dicated that the fetal epigenome is vulnerable to envir-
onmental exposures, such as methyl group availability
from the maternal diet [30–36].
Imprinted genes are a paradigm for the transmission of
epigenetic information across generations. Methylation
differences between the paternal and maternal copies of
imprinted genes are established in the germ cells and are
known to be important for transcriptional regulation. Ac-
cordingly, inappropriate loss or gain of methylation at im-
print control regions (ICR) is a diagnostic feature for
several human disorders. These regions are protected
from the wave of demethylation which occurs prior to im-
plantation by several factors, such as PGC7/STELLA [37]
and ZFP57, a Krueppel-associated box (KRAB) domain
zinc finger protein [38, 39]. Several studies to date have
centered on analyzing the effects of nutrition in particular
on imprinted genes [31–33, 40] and have shown that not
only can altered diet result in an altered epigenotype, but
it can also affect phenotype and predisposition to child-
hood and adulthood disease [41].
We have previously reported data from a random-
ized controlled trial of Folic Acid Supplementation in
the Second and Third Trimester (The FASSTT Trial;
ISRCTN19917787) where we found supplementation
led to significant protection against folate depletion in
mothers and offspring [42] and more recently that this
led to differences in DNA methylation at some
imprinted loci by using a candidate gene approach
[43]. Here, we used the Infinium Methylation EPIC
Beadchip Array to profile genome-wide DNA methyla-
tion levels in cord blood in an unbiased screen for re-
gions susceptible to DNA methylation changes in
response to altered FA levels. We report here that the
top candidate region affected is a differentially methyl-
ated region (DMR) upstream of the gene encoding
ZFP57. We verified our finding using pyrosequencing
in cord blood and also show that the region responds
to FA supplementation in maternal blood. Addition-
ally, we confirm that altering methylation results in
changes in ZFP57 transcription.
Results
Maternal FA supplementation significantly improves
folate status in mother and baby
For the current analysis, the same 86 cord blood samples
from the FASSTT trial (outlined in Fig. 1) which had been
analyzed previously for candidate gene methylation [43]
were used: a summary of the most pertinent characteris-
tics are given in Table 1 for convenience. At baseline (ges-
tational week 14 (GW14)), there were no detectable
differences between the treatment and placebo groups in
maternal characteristics, dietary folate intakes, serum or
red blood cell (RBC) folate concentrations, or in MTHFR
status, as expected following randomization. There were
also no significant differences in neonatal characteristics
such as weight, length, and head circumference(Table 1).
However, as a result of treatment with FA during tri-
mesters 2 and 3, maternal serum and RBC folate be-
came significantly different between placebo and
treated group, as previously reported from this trial.
The normal decline in maternal folate biomarkers pre-
viously reported from observational studies during
pregnancy is mirrored in the placebo group where
serum folate decreased from 48.8 to 23.6 nmol/L be-
tween GW14 and GW36 (Table 1). FA supplementa-
tion served to protect the mothers in the treatment
group, where folate concentrations remained stable
over the course of pregnancy (i.e., serum folate 45.8
nmol/L at GW14 and 46.5 nmol/L at GW36). Cord
serum and RBC folate concentrations were also
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significantly higher in infants of the mothers supple-
mented with FA compared with those from the pla-
cebo mothers (Table 1). RBC folate concentrations in
mothers and offspring were strongly correlated (r = 0.619;
p = < 0.001, Additional file 1: Figure S1).
Widespread alterations to DNA methylation levels in cord
blood in response to late gestation maternal FA
supplementation
DNA was purified from cord blood and quantified
prior to bisulfite conversion and hybridization to the
Infinium Methylation EPIC Beadchip Array, which
covers more than 850,000 CpG sites distributed across
the genome. Methylation values are expressed as a
decimal value β between 0.0 (no methylation) and 1.0
(fully methylated). Data were analyzed and visualized
using the RnBeads package in RStudio (see methods
section). As a control, a quantile-quantile (QQ) plot of
observed versus expected chi-squared values was gen-
erated and showed no evidence of population sub-
structure effects (Additional file 2: Figure S2).
Figure 2a is a scatterplot showing mean β value for
each CpG site analyzed in treated versus placebo sam-
ples. Overall, methylation at individual CpG remains
closely correlated (ρ = 0.998) between the two groups
as expected, with most sites falling along the diagonal.
Sites which differed in methylation between placebo
and treatment groups were automatically ranked by
RnBeads, which uses a combination of the change in
mean methylation, the quotient of mean methylation
Fig. 1 FASSTT study outline for samples used in this study. Eligible pregnant women (n = 226) were randomized into two groups: placebo
(n = 94) and folic acid (n = 96). Women withdrew (n = 25) or were excluded from the intervention for the reasons indicated. A total of 119
women completed the trial. Blood samples were taken at gestational weeks (GW) 14 (pre-intervention) and 36 (post-intervention). Cord
blood samples (n = 86) were taken at birth
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and the combined p value, and the 1000 top-ranking
sites are highlighted in red in Fig. 2a. This metric was
developed to take into account not only p value but the
magnitude of the change in methylation and in our experi-
ence is a more reliable indicator of biologically meaningful
differences than p value alone. Sites falling along either side
of the diagonal, representing gains and losses in methyla-
tion after treatment, can both be seen, with a tendency to
greater numbers of sites losing. Consistent with this, a
methylation density distribution plot shows that after treat-
ment there was a clear decrease in the numbers of sites in
the top quartile for methylation (β = 0.75–1.00; Fig. 2b).
Taking the top 1000 ranking sites overall, approxi-
mately 2/3 (n = 658) lost and 1/3 (n = 342) gained
methylation (Fig. 2c). However, the magnitude of
these changes was generally modest, with only 302
(193 + 109) losing or gaining more than 5% methyla-
tion, the minimum change which we could potentially
Table 1 General characteristics of participants from the EpiFASSTT trial
Characteristic Placebo (n=45) Folic acid (n=41) P value
N = 45 N = 41
Mean SD Mean SD
Maternal characteristics (GW14)
Age (years) 28.9 3.5 29.4 3.9 0.513
BMI (kg/m2) 25.2 3.9 24.9 4.6 0.768
Smoker n (%) 8 (18) 6 (15) 0.693
Alcohol n (%) 3 (7) 1 (2) 0.618
Parity (n) 1 (1.1) 1 (1.0) 0.915
MTHFR 677TT genotype n (%) 5 (11) 2 (5) 0.291
Dietary intakes
Energy (MJ/d) 8.170 1.717 7.732 1.595 0.280
Dietary folate equivalents (μg/d) 364 172 387 152 0.582
Vitamin B12 (μg/d) 4.1 1.9 3.9 1.8 0.791
Neonatal characteristics
Gestational age (weeks) 40.1 1.3 40.0 1.1 0.540
Sex, male n (%) 22 (49) 22 (54) 0.659
Birth weight (g) 3610 475 3557 465 0.601
Birth length (cm) 51.5 2.6 51.1 2.2 0.499
Head circumference (cm) 34.9 1.2 34.8 1.4 0.907
Apgar score at 5 min 8.4 0.4 9.0 0.3 0.220
Caesarian n (%) 11 (24) 10 (24) 0.995
B-vitamin biomarkers
Maternal pre-intervention (GW14)
Serum folate (nmol/L) 48.8 19.8 45.8 19.5 0.469
RBC folate (nmol/L) 1185 765 1181 649 0.978
Serum B12 (pmol/L) 224 79 217 79 0.601
Maternal post-intervention (GW36)
Serum folate (nmol/L) 23.6 17.9 46.5 24.8 < 0.001*
RBC folate (nmol/L) 991 404 1556 658 < 0.001*
Serum B12 (pmol/L) 168 51 157 60 0.229
Cord blood
Serum folate (nmol/L) 68.3 24.8 91.7 36.7 0.004*
RBC folate (nmol/L) 1518 597 1877 701 0.024*
Serum B12 (pmol/L) 276 155 251 107 0.776
Statistical comparisons by independent t test (continuous variables) or χ2 test (categorical variables)
GW gestational week, BMI body mass index, RBC red blood cell
*p < 0.05
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verify using pyrosequencing, and only 76 sites losing
or gaining more than 10% (Fig. 2c).
We examined the top-ranking sites as identified by
RnBeads (Fig. 2d): of these, the CpG site in the ATP11A
gene contained a single nucleotide polymorphism (SNP)
missed by the quality control routines; the same was true
of the CpG at the MAGI2 gene. The presence of the SNPs
at these CpGs leads to the erroneous appearance of a
change in methylation, so these were discounted. Two of
the other top-ranked sites were at the PRKAR1B locus,
which encodes a regulatory subunit of cyclic AMP-
dependent protein kinase A, and one was at NXN, a mem-
ber of the thioredoxin superfamily; however, all three were
listed as located in the respective gene body and so are
less likely to contribute to transcriptional control. Never-
theless, to verify these, we used a second method utilizing
commercial pyrosequencing methylation assays (pyroas-
says) designed to query the same CpGs. These reported
smaller average differences in methylation between treated
and placebo groups than seen with the array of 6.6% for
cg08104960 at NXN, and 4.2% (cg06242242) and 2.2% for
(cg05729249) for the sites at PRKAR1B: only the site at
NXN was significant (p = 0.002, t test).
Identification and verification of a differentially
methylated region upstream of ZFP57
Given that single sites are more susceptible to con-
founders such as the presence of SNPs and show only
moderate accuracy on verification, and to maximize our
chances of finding biologically significant changes, we
also looked for genomic intervals showing coherent al-
terations in methylation across multiple neighboring
sites [44], rather than isolated CpGs. Figure 3a lists the
top 5 differentially methylated regions (DMR) found at
promoters, ordered by RnBeads ranking which is here
computed by combining measures at adjacent sites
Fig. 2 Widespread alterations to DNA methylation levels in cord
blood in response to late gestation maternal folic acid
supplementation. a Scatterplot comparing mean methylation levels
(β values 1 = 100%; 0 = 0% methylation) at individual probes in
placebo and treated groups. The 1000 top-ranking sites between
groups are highlighted in red: ρ = correlation value. b Probe
methylation density plot comparing the distributions of methylation
values per sample group. In the treatment group, there is a decrease
in the number of fully methylated sites (β > 0.75). c Split in top 1000
ranking sites losing or gaining methylation overall. Also shown are
numbers of sites showing changes greater than 5% or 10%. d Top 5
differentially methylated sites overall, sorted by combined rank, the
value being computed as the maximum (i.e., worst) value among
the mean quotient log, mean difference in methylation and p value
(P). No., number; Chr, chromosome; Position, coordinates in hg19
human genome release; CG probe, identity number of the
CpG probe on the EPIC array; % change, difference in mean β value
expressed as %; Gene, nearest gene; P, probability (uncorrected);
Rank, RnBeads computed ranking value (lowest being best)
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using a linear hierarchical model as described in the
“Methods” section: uncorrected p value and % change
in methylation are also shown for comparison. For the
top 5 regions, ZFP57 was of particular interest and is dealt
with below. Two others (CES1, a liver carboxylesterase, and
ANKRD20A11P, a pseudogene) showed less than 5%
change in methylation and so could not be verified:
DUSP22 which has a larger change is also a pseudogene.
The last DMR is located at a microRNA cluster
MIR4520A/B and loses approximately 7.22% overall in the
treatment group, averaged over a number of well-spaced
CpG. Due to pyrosequencing assay design constraints, we
could only cover one site (cg08750459) from the array at
this locus but that site showed reasonable concordance
(loss of 12.24% (p = 0.008) in array and 9.45% (p = 0.006) by
pyroassay). The function of these microRNAs remains ob-
scure however.
Of more interest in the context of this cohort was the
highest ranking promoter DMR identified using
RnBeads [45], which was located on chromosome 6, the
closest gene being the known regulator of genomic im-
printing ZFP57. The identified DMR consisted of 15
CpG sites and mapped approximately 3 kb upstream of
the first exon of the gene, a region containing add-
itional adjacent sites also gaining methylation. Figure 3b
shows a genomic map of the first exon of ZFP57 and
Fig. 3 Top ranking promoter regions included imprint regulator gene ZFP57. a Top 5 differentially methylated regions (DMR) at promoters, sorted
by combined RnBeads rank (smallest to largest) as for Fig. 2d above, except combining values across all the CpG sites in the DMR as detailed in
the “Methods” section. Abbreviations as above except # probes, number of probes on EPIC array included in DMR. b Top: genome browser tracks
showing the region around the DMR upstream of ZFP57, genomic coordinates in hg19 human genome release, and scale as shown. EPIC array
probes showing differential methylation (blue, gain; red, loss) are indicated, with size indicating the magnitude of change. The start of the ZFP57
gene and the position of the pyrosequencing assay (Pyro) are also shown. Δβ, mean difference in β value between placebo and FA-treated
groups; maximum gain and loss also shown (+ 0.09 β = 9% methylation). Bottom: Loess plot of β values across the region, with CpG identification
numbers from array below; those forming the DMR defined by RnBeads are indicated, as well as sites analyzed by pyroassay. Each dot represents
β value in an individual sample, with lines representing smoothed averages; color code is indicated at left. c Results of pyroassay covering the six
sites indicated in b. Sample groups: cord blood DNA from placebo (n = 45) and FA-treated (n = 41). Mean, average of the individual means in that
group; Max., largest of the mean methylation values in that group; Min, lowest mean in group; SD, standard deviation for the means; Change,
difference in % methylation seen between groups; P, probability (Student’s t test)
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the upstream region, overlaid with a track showing the
locations of EPIC probes and whether they gained or
lost methylation. Also shown is a graph of averaged
methylation values at the numbered CpG probes from
the array in placebo and treatment groups, showing a
clear difference in methylation extending beyond the
DMR. To confirm these results using a second method,
we designed a pyrosequencing methylation assay (pyr-
oassay) to cover some of these CpG sites, as shown in
Fig. 3b. Due to the CpG density of this region, thus dif-
ficulty in pyrosequencing primer design, our pyroassay
is not directly overlapping all CpGs identified by
RnBeads as the DMR but is inside the area showing
methylation differences. We then carried out PCR and
pyrosequencing for all the samples. The overall gain in
methylation at the CpGs covered by the pyroassay (n =
6) was very similar in magnitude and direction to that
seen over the neighboring CpG by the array (+ 5.44% vs
+ 6.23%, respectively—Fig. 3a, c).
Demethylation of the upstream region was accompanied
by increased ZFP57 transcription
Having established that methylation differences at the up-
stream DMR are evident between FA-supplemented and
placebo-treated controls, we wished to test mechanistically
if such differences could impact on transcription from the
downstream gene. To do this, we first used a well-estab-
lished model, the paired colorectal cancer lines HCT116
and its derivative HCT116 DKO (double knockout), which
carries mutations in two of the methyltransferase genes
DNMT1 and DNMT3B and is known to be hypomethy-
lated at many loci [46]. Methylation array data available
in-house showed differential methylation between the par-
ental or wild type HCT116 (WT) and paired DKO cells at
the same region upstream of ZFP57 found in the FASSTT
cohort, indicated by red colored bars whose height is pro-
portional to the loss of methylation (Fig. 4a); this indicates
that DNMT1 and DNMT3B are required for methylation
at this locus. We confirmed these results using our pyr-
oassay, which showed > 80% methylation in WT
HCT116 cells and a drop to < 20% in DKO cells (p
= < 0.001) (Fig. 4b).
To determine if methylation at this upstream region
can regulate transcription at the ZFP57 gene 3 kb down-
stream, we designed primers to cover part of the tran-
script as shown in Fig. 5a (FW/RV) and carried out
reverse transcription on mRNA from the cells followed
by polymerase chain reaction (RT-PCR). While minimal
transcript could be detected in the HCT116 WT cells,
which are heavily methylated, signal was readily apparent
in the demethylated DKO cells (Fig. 4c). We confirmed
this expression pattern quantitatively using RT-qPCR
(Fig. 4d). While these results show that the gene can be
de-repressed in response to loss of methylation, it is
normally not expressed in colon cells, from which
HCT116 were derived, so we used the neuroblastoma
cell line SH-SY5Y to test the effect of methylation
changes on transcription in a neural cell type. ZFP57 is
normally transcribed in neural tissue as well as early
embryo [47], but shows some methylation in the
SH-SY5Y cells, which may be due to differences among
neural cell types, or reflect accumulation of methylation
during culture; however, these cells are likelier than
HCT116 to contain neural-specific transcription
factors. Here, we used a second method to perturb
methylation, namely treatment with the DNA methyl-
transferase inhibitor 5′aza-2′deoxycytidine (5-aza-dC).
Exposure of the cells to this small molecule inhibitor
caused loss of methylation at the upstream region
(Fig. 4e). RT-PCR confirmed that ZFP57 was
de-repressed upon treatment with 5-aza-dC (Fig. 4f ).
Quantification of mRNA levels with RT-qPCR again in-
dicated a substantial increase in transcription from the
gene in response to loss of methylation (Fig. 4g).
Greater variability at imprinted DMR in folate-treated
samples
These results suggest that the increased methylation
seen at the ZFP57 upstream region will lead to de-
creased transcription. Since ZFP57 plays a role in main-
taining methylation specifically at imprinted genes, we
examined methylation levels at these regions using data
from the EPIC array. We used germline differentially
methylated regions as defined by [48] and assessed
average methylation across all probes which fell within
these intervals. We excluded DMR which were flagged
as acquiring methylation differences somatically and
also germline DMR where methylation as assessed by
the array fell outside the 35–65% methylation range de-
fined as normal in that study. This left 15 imprinted
germline DMR for which the median methylation level
fell within the normal range in the placebo group
(Additional file 3: Figure S3A). Comparing the samples
from the folate supplemented group, only the
maternally imprinted neuronatin gene (NNAT) showed
a small but significant loss of methylation in the
treatment group (p = 0.022, Mann-Whitney U test
(MWU)) but there was no significant difference be-
tween placebo and treatment for any other DMR. How-
ever, it was notable that 11/15 DMR showed a
significantly greater variability in methylation in treated
participants (p = < 0.001, chi-squared test), which can
be seen from the greater interquartile range (IQR—see
Additional file 3: Figure S3A). Along with this greater
variability in the treatment group, the median methy-
lation levels trended lower than the placebo group
for almost all imprinted genes (Additional file 3:
Figure S3A). We repeated this analysis using
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imprinted DMR as defined by Court et al. [49],
which defines slightly larger DMR based on an ana-
lysis of Illumina 450 K data. After applying similar
criteria as above, this left 14 DMR suitable for com-
parison. Using these genomic intervals, again, only
NNAT showed a significantly different level of methy-
lation in treated samples (p = 0.022, MWU; Add-
itional file 3: Figure S3B), although PLAG1 was also
close to significant (p = 0.072, MWU). Again, the IQR
for the imprints showed greater variability in the
treated than placebo groups (p < 0.001, chi-squared
test) and medians tended to be lower in the
FA-treated group (Additional file 3: Figure S3B).
Increased ZPF57 methylation in response to FA in
maternal blood samples
In order to investigate the effects of FA in maternal tis-
sue, and to elucidate if this differentially methylated re-
gion upstream of ZFP57 was directly responsive, we
carried out pyrosequencing on matched maternal buffy
coat samples at GW14 (n = 24) and GW36 (n = 24) (i.e.,
comparing the same mother’s blood sample taken be-
fore and after intervention). Pyrosequencing analysis
confirmed that FA-supplemented mothers show a
5.51% increase in DNA methylation levels at this DMR
after late gestation supplementation (p = 0.609), in con-
trast to non-supplemented mothers, whose methylation
levels decreased 1.51% at GW36 (p= 0.826) (Table 2).
Effect of FA at the ZFP57 DMR in a second cohort
In order to test the generality of the effect of folic acid
intervention on this genomic region, we examined data
from a second randomized-controlled trial. The Aber-
deen Folic Acid Supplementation Trial (AFAST) was an
RCT using two doses of folic acid (0.2 and 5 mg/day vs
placebo) during pregnancy, with intervention starting
at antenatal booking at < 30 weeks gestational age [50].
The study was conducted in the late 1960s, and re-
cently, Richmond and colleagues [35] followed up on
the offspring born to the mothers who had participated
in the trial, mean present age of 47 years. Saliva samples
were collected from those who could be identified and
Fig. 4 ZFP57 upstream region is a methylation-dependent regulator of transcription at this locus. a Schematic as in Fig. 3 above but showing
difference in methylation (Δβ) between HCT116 WT cells vs HCT116 DKO cells. The intron/exon structure and positions of the forward (FW) and
reverse (RV) primers for RT-(q)PCR on the ZFP57 gene are also shown. b Methylation levels at individual CpG covered by the pyrosequencing assay in
WT (HCT116) and knockout (DKO) cells. Values are shown as mean +/− SD for each site: *p < 0.05; **p < 0.01; ***p < 0.001. c RT-PCR showing
upregulation using the primers indicated in a, key as above. CTRL, positive control (human reference total RNA); NTC, negative control (no template
control); 100 bp, size standards ladder; ACTB, β-actin loading control. d Confirmation of upregulation by RT-qPCR using the same primers, values
normalized to HPRT; FC, fold change. e Methylation levels using pyroassay as in B but in 5-aza-dC treated SH-SY5Y cells (5-aza-dC), as compared to
untreated (UT). f RT-PCR for 5-aza-dC treated cells from e. g RT-qPCR confirmation of ZFP57 upregulation in 5-aza-dC-treated SH-SY5Y cells
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consented, with subsequent 450 k array analysis con-
ducted using modeling approaches to correct for hid-
den variables such as cell counts [35]. Examination of
the CpG in the ZFP57 DMR which we had identified in
the EpiFASSTT cohort showed the same trends in the
AFAST high-folate cohort versus placebo, with change
in a positive direction across the whole region (Fig. 5a),
although effect size was lower at each site in the
AFAST study (Fig. 5b).
Discussion
We have previously reported DNA methylation differ-
ences at imprinted loci using cord blood from the Epi-
FASSTT trial of folic acid (FA) supplementation in later
pregnancy by using a candidate gene approach. Here, we
used the same samples to carry out an unbiased
genome-wide screen for methylation differences using the
EPIC array. The top hit was a differentially methylated re-
gion upstream of the imprint controller ZFP57, and we
separately verified methylation differences by pyroassay.
This region responded to FA supplementation in maternal
blood as well as in cord blood and showed differences be-
tween FA-treated and untreated in an independent cohort
[50]. Altered methylation at ZFP57 was associated with in-
creased variation in methylation at imprinted loci in cord
blood. We also showed using two separate cell line models
that altering methylation at the ZFP57 upstream region
can affect transcription, indicating a potential feedback
mechanism may be operating here. We were also able to
identify and verify methylation changes at a number of
other individual CpG sites including some in the gene
bodies of the NXN and PRKAR1B genes and at the start
ZFP57
2 kbhg19chr6:29,651,000- 29,642,000
AFAST_Effect_Size
EPIFASSTT_Effect_Size
_ 0.143641
_ 0
_ 0.461193
_ 0
A
B 
Fig. 5 Comparison of AFAST and EpiFASSTT data for the DMR. a Effect size (Cohen’s d) at each CpG in the ZFP57 DMR was calculated by
comparing high dose and placebo from the AFAST study and plotted against the locus (top track). A similar analysis was done for the EpiFASSTT
data (bottom track). Maxima are indicated at right, scale bar and location at top; note: no other CpG outside the DMR are shown in this analysis.
b The two sets of values from a are plotted on the same scale to give an indication of comparability
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of the MIR4520A/B gene, but these were less likely to
have functional consequences. It is notable also that we
found more decreases in methylation genome-wide
than increases, which may seem counter-intuitive; how-
ever, we and others have reported similar response to
FA previously [43, 51]. It is has been suggested that FA
may cause feedback inhibition by altering the SAM to
SAH ratio and therefore the intracellular methylation
potential [52].
Uncovering a DMR at a region controlling ZFP57 tran-
scription as the top hit in an unbiased screen was particu-
larly striking in the EpiFASSTT randomized controlled
trial, where we have already shown, using a candidate gene
approach, that methylation levels were perturbed at some
imprinted loci. The primary importance of ZFP57, as de-
scribed in the literature from mechanistic work, is in
maintaining imprinting, and it is currently the only pro-
tein known to be dedicated solely or largely to this epigen-
etic process [53]. ZFP57 was discovered as a maternal-
zygotic effect gene which was required in mice for es-
tablishing methylation at some imprints in the oocyte,
and for maintaining all imprints, both maternal and pa-
ternal, in the preimplantation embryo [38]. It does this
by binding to a conserved hexamer consensus sequence
(5′-TGCme5CGC-3) found at all imprinting control re-
gions (ICRs) [54, 55], recognizing the methylated CpG
in this motif, as shown in a crystallographic study [56].
Deletion of mouse Zfp57 causes a loss of methylation
from the modified parental allele by mid-gestation, with
subsequent dysregulation of transcription at imprinted
loci and embryonic lethality [55]. Importantly, muta-
tions in the human homolog ZFP57 are also associated
with hypomethylation of multiple imprinted loci, indi-
cating a conserved role in human for this gene in main-
taining imprints [39].
Although this is the first report, to our knowledge, from a
randomized controlled trial of FA intervention which impli-
cates methylation changes at ZFP57, it was previously re-
ported from a small observational study (n = 23) that
maternal folate concentrations in the third trimester were
associated with changes at a DMR at the same genomic lo-
cation [51] when cord blood DNA methylation levels at
birth were profiled. While that study reported a loss rather
than gain of methylation, it was not an RCT but an
observational study, and so could not test the effects of fol-
ate supplementation directly in a controlled fashion: there
were many other differences in study design, numbers of
participants, and analysis methods. It should also be noted
that the high folate group in that study had levels of serum
folate almost twice those seen in our treated samples (74.59
+/− 6.1 nmol/L Amarasekera et al. vs 46.5 +/− 19.5 nmol/L
GW36 treated group in this study), highlighting that we are
protecting normal folate levels rather than elevating them.
Although the largest-to-date observational study, com-
prising a meta-analysis of the MoBa (n = 1275) and
Generation R (n = 713) cohorts, did not identify this re-
gion as a top hit, they could confirm that five CpG sites
within this 923 bp region were significantly altered,
though not the direction of change [57]. These two pa-
pers reporting changes from different observational
studies nevertheless lend considerable support to this
being a true folate-sensitive DMR. We could also verify
using a separate biological assay the magnitude and dir-
ection of change in methylation, a gain of 5.44% in the
treatment group, at the DMR in cord blood by using
pyrosequencing (p = 0.172). Furthermore, by comparing
the mother’s pre- and post-intervention, we could show
that this region also gained methylation in the treated
mothers, but lost methylation in the placebo group,
providing a further degree of validation.
To extend our findings, we also used data from one of
the few other RCTs testing the role of folic acid during
pregnancy, the AFAST study [50]. We found a small effect
(Cohen’s d < 0.2) at all the CpG across the ZFP57 DMR,
whereas there was a medium effect (Cohen’s d < 0.5) seen
at the same region in the EpiFASSTT study. The effect in
AFAST was only seen with the high dose of FA (5mg/
day) vs placebo, rather than the lower dose (200 μg/day)
which was closer to that used in EpiFASSTT (400 μg/day),
and the effect size was smaller than that seen in Epi-
FASSTT. There may be a number of reasons why effect
size was smaller in AFAST: (1) the time between exposure
and measurement is much greater, with median age 47
years in AFAST, vs newborns in EpiFASSTT; (2) the
AFAST participants used were recruited significantly later
than other groups (20.2 weeks for high dose vs 16.3 for
low dose), meaning that there was less time spent exposed
to the additional FA while in the womb; (3) the AFAST
Table 2 ZFP57 methylation in maternal blood pre- and post-intervention. DNA methylation levels of ZFP57 DMR in maternal blood
samples at GW14 and GW36.
Sample group Gestational week (GW) Mean methylation (%) Standard deviation (SD) Change in methylation (%) p values
Treatment
(n = 24)
GW14 57.47 15.37 + 5.51 0.609
GW36 62.98 14.94
Placebo
(n = 24)
GW14 64.36 6.58 −1.51 0.826
GW36 62.85 7.13
GW gestational week, SD standard deviation
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DNA samples were derived from saliva, while the Epi-
FASSTT DNA samples are from cord blood; and (4) the
final numbers for the AFAST comparisons were very low
(5mg/day n = 23; placebo n = 43). Notwithstanding these
limitations, the AFAST study showed a similar effect in
terms of direction and magnitude at the same region up-
stream of ZFP57, providing further evidence that this is a
bona fide FA sensor.
Given the role of ZFP57 in imprint maintenance, we
also took advantage of the array to examine imprinted
genes in our samples. Of these, only the maternal imprint
NNAT (neuronatin) showed a small but significant loss of
methylation in the treatment group, consistent with other
evidence [58]. NNAT is highly expressed in the brain and
placental tissue and functions during brain development
to regulate ion channels and maintain hindbrain and pitu-
itary segment identity [59]. ZFP57 is essential for the
maintenance of this imprint [38]. Induction of increasing
mRNA levels of NNAT commences at midgestation in as-
sociation with neurogenesis and peaks upon neuroepithe-
lial proliferation and neuroblast formation [60], which
would coincide with when folate concentrations increased
in the treated group. Although we previously reported sig-
nificant differences overall at IGF2, and at some CpG for
GRB10, in our candidate gene approach using these sam-
ples [43], that was based on pyroassays which covered
smaller regions of the imprinted DMR, whereas the
probes from the array are more dispersed and cover a lar-
ger area. It was also notable that, while there was little
change at other imprinted DMR as assessed by the array,
there did appear to be an increase in the variability of
methylation at these regions, an effect which was small
but statistically significant and consistent with findings
from a mouse model where FA supplementation increased
variance in methylation levels across generations [61].
Given that ZFP57 has a role in maintaining imprints, in-
creased methylation at the upstream controller as seen in
our FA-treated samples should lead to decreased tran-
scription of ZFP57, which could potentially lead to re-
duced ability to maintain imprints and increased
variability in methylation at the ICR. These possibilities
can be further explored using our in vitro cell models.
It remains to be established from mechanistic studies
in mouse whether ZFP57 plays any role in maintaining
methylation in vivo in the post-implantation embryo. It
is also possible that methylation of the DMR in human
blood may not reflect the methylation levels seen at earl-
ier stages, or in tissues which normally express the gene,
which includes oocytes and some neural cells. It may be
that methylation levels at the ZFP57 DMR reported here
reflect changes which have occurred in the cord and ma-
ternal bloods independently of what is occurring in the
germline, and this would need to be assessed. It is also
quite likely, given that imprints are thought to be
established much earlier during development, that it
would not be until the next generation that effects at
imprinted germline DMRs could be seen. In this context,
several studies have pointed to transgenerational rather
than intergenerational effects at imprinted loci [62, 63].
It should also be noted that methylation levels varied
substantially across the ZFP57 DMR and between indi-
viduals (max = 94.97, min = 20.95), unlike the imprinted
DMR which vary much less and may be buffered against
methylation changes by multiple mechanisms.
In addition to its well-established role in imprinting,
ZFP57 has also been proposed to act as a transcriptional
repressor in Schwann cells, which comprise the principal
glia of the peripheral nervous system [47]. Recent work
from our group has indicated children born from
mothers supplemented with FA in late gestation have
psychosocial developmental benefits, scoring signifi-
cantly higher for emotional intelligence and resilience in
comparison with children not exposed to FA supple-
mentation in later pregnancy [64]. Further work needs
to be carried out to check if there are any other novel
targets of ZFP57 which may be affected in later child-
hood and adulthood.
We sought to clarify whether an increase in methyla-
tion at the ZFP57 DMR as seen in this RCT would have
a substantial effect on the production of the protein. In
order to explore whether changes in methylation can
alter transcription, we utilized cell lines where the only
variable was the presence or absence of DNA methyla-
tion. Our results from these two systems (HCT116 cells
with methyltransferase deficiency and SH-SY5Y cells
treated with an inhibitor) showed that altering methyla-
tion alone can cause changes in transcription at the
ZFP57 locus and that this is linked to changes in
methylation at the DMR. Our results therefore support
the hypothesis that the DMR represents an upstream
control element for the gene, which we have shown
from the RCT is sensitive to methyl donor status in the
diet. Little is currently known about the factors control-
ling ZFP57 transcription. Interestingly, the region con-
taining the DMR does not appear to be conserved in
mice and so may represent a human-specific element.
However, it has features characteristic of a control
element, as from examining publicly available datasets
on the UCSC genome browser, there are DNAse I
hypersensitive sites present here and data suggesting
transcription factors may bind. We are currently ex-
ploring these aspects of the work further.
Conclusions
Despite the limitations discussed above, we have never-
theless shown conclusively that a region upstream of the
imprint controller ZFP57 shows changes in methylation
in mothers in response to intervention during later
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pregnancy with FA, a methyl donor, and that this effect
is also evident in the cord blood in their offspring. Our
findings are borne out by other observational studies as
well as an independent RCT [50]. We have also clearly
demonstrated that altering methylation is sufficient in it-
self to cause changes in transcription of the gene. These
results have implications for the control of imprinting by
environmental inputs and uncover a novel transcrip-
tional control element which may be involved in this
process.
Methods
Study design and sample collection
Samples were acquired from the FASSTT (folic acid sup-
plementation in the second and third trimester) study
cohort, a previously conducted double-blinded, random-
ized controlled trial in Northern Ireland described in full
previously [42, 43]. To summarize in brief, women with
singleton pregnancies were recruited at approximately
14 weeks of gestation from antenatal clinics at the
Causeway Hospital, Coleraine (n = 226; Fig. 1). Women
were excluded from participation if they were taking
medication known to interfere with B-vitamin metabol-
ism or if they had any vascular, renal, hepatic, or gastro-
intestinal disease, epilepsy, or had a previous
NTD-affected pregnancy. Prior to randomization, n = 36
women withdrew from the study. The remaining eligible
participants at the end of their first trimester were ran-
domized into two groups; one group received 400 μg/d
folic acid (n = 96) and the other a placebo in pill form (n
= 94) until the end of their pregnancy. Randomization
was done on a double-blind basis. Maternal non-fasting
blood samples were taken at gestational week 14
(GW14), prior to intervention commencement, and at
GW36, towards the end of the intervention. The study
was completed by 119 women, as 71 participants were
excluded during the study (see Fig. 1). A total of n = 37
women were excluded from the folic acid group for the
following reasons: participant withdrawal n = 11, preg-
nancy complications n = 13, prescribed folic acid n = 6,
fetal death n = 6, non-compliance n = 6. A total of n
= 34 women were excluded from the placebo group for
the following reasons: participant withdrawal n = 14,
pregnancy complications n = 8, prescribed folic acid n
= 5, fetal death n = 2, non-compliance n = 3, hospital
transfer n = 2. Umbilical cord blood samples were col-
lected after the expulsion of the placenta at delivery,
along with birth weight, length, head circumference,
mode of delivery, and Apgar score.
Blood sample processing and B-vitamin biomarker
determination
Blood samples were collected in EDTA-lined tubes, kept
refrigerated, and processed within 4 h (excepting cord
blood, processed within 24 h). Blood samples were ana-
lyzed for serum and red blood cell folate and vitamin
B12 via microbiological assay as previously described
[65, 66]. The buffy coat was used for methylenetetrahy-
drofolate reductase (MTHFR) 677C > T genotyping as
described [67]. Quality control was affirmed by repeated
analysis of stored batches of pooled samples. Intra- and
inter-assay CVs were ≤ 8.2% for serum and RBC folate
and ≤ 10.4% for serum vitamin B12.
Maternal dietary analysis
Dietary data was collected using a 4d food diary in com-
bination with a food-frequency questionnaire during the
second trimester of pregnancy, with particular emphasis
on a B-vitamin-fortified food intake. Dietary analysis was
carried out using WISP version 3.0 (Tinuviel Software,
UK) modified to segregate naturally occurring folate in
foods versus folic acid fortification of foods; these were
combined to enable calculation of dietary folate
equivalents.
Cell culture
HCT116 and double knockout (DKO) cells [46] were
cultured in 1 g/L glucose DMEM supplemented with
10% FBS and 1× NEAA (Thermo Scientific, Loughbor-
ough, UK). SH-SY5Y cells were cultured in DMEM/F12
medium supplemented with 10% FBS (Thermo Scien-
tific). For treatment with 5′aza-2-deoxycytidine
(5-aza-dC) (Sigma-Aldrich, Dorset, UK), SH-SY5Y cells
were seeded onto a 90-mm plate in complete medium,
and the following day medium was replaced and supple-
mented with 5-aza-dC at a final concentration of 1 μM,
which was renewed at 24-h intervals up to 72 h. Cells
were then harvested for DNA and RNA extraction.
Transcriptional analysis
RNA was extracted using the RNeasy Mini kit (Qiagen,
Crawley, UK) according to manufacturer’s instructions.
Complementary DNA (cDNA) was synthesized and
RT-qPCR/RT-PCR were carried out as previously [29].
Primer sequences are listed in Additional file 4: Table
S1. Human reference total RNA was used as a positive
control for expression (Clontech, UK).
DNA extraction, bisulfite conversion, and Infinium
MethylationEPIC Beadchip Array
Genomic DNA was extracted from cultured cells as pre-
viously described [25] and from cord blood using the
QiAMP DNA Blood Mini kit (Qiagen), according to
manufacturer’s instructions. Purity and integrity of DNA
were assessed by agarose gel electrophoresis and using
the Nanodrop 2000 spectrophotometer (Labtech Inter-
national, Ringmer, UK). DNA quantification was deter-
mined using Quant-IT PicoGreen dsDNA Assay Kit
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(Invitrogen, Paisley, UK). The DNA at a concentration
of 50 ng/μl was sent to Cambridge Genomic Services
(Cambridge, UK), who bisulfite converted the DNA
in-house using the EZ DNA Methylation Kit (Zymo Re-
search, California, USA) prior to hybridization to the
Infinium Human Methylation EPIC BeadChip Array and
scanning with the Illumina iScan according to manufac-
turer’s instructions (Illumina, Chesterford, UK).
Bioinformatic analysis
GenomeStudio (Illumina v3.2) was used for initial data
processing. Subsequently, idat files were imported into
the RnBeads package (version 1.6.1) [45] in the freely
available statistical software platform R (version 3.1.3)
using the R Studio interface (Version 0.99.903). Samples
were quality control checked including removal of
probes with missing values, containing SNPs, or of poor
quality using the greedycut algorithm, then sex chromo-
somes were removed from the analysis. Background cor-
rection was carried out using methylumi.noob and the
methylation values of the remainder probes were nor-
malized using bmiq [68]. Initial data exploration in
RnBeads used principal components analysis (PCA) to
explore potential correlations between the groups and
known confounders such as BMI, smoking, and gender.
In addition, in order to account for any hidden con-
founding variables in the dataset, surrogate variable ana-
lysis was carried out using the sva package with the Buja
and Eyboglu algorithm from (1992) [69] Briefly, potential
surrogate variables such as age, sample plate, Sentrix ID,
and Sentrix Position were tested for association with the
target variable sample group using PCA and any surro-
gate variable with a high correlation to sample group
was adjusted for and incorporated into the making of
the limma based linear model. The methylation inten-
sities for each probe, each representing a CpG site, were
represented as β values (ranging from 0, unmethylated,
to 1, fully methylated), and these were plotted against
genomic loci (based on hg19-Human Genome Build 19)
using GALAXY software (https://usegalaxy.org/) [70] in
order to visualize changes in DNA methylation on the
University of California at Santa Cruz genome browser
(https://genome.ucsc.edu/) as described previously [71].
Bisulfite pyrosequencing
Primers spanning the probes of interest from the array
were designed using the PyroMark Assay Design Soft-
ware 2.0 and bisulfite-treated DNA PCR-amplified using
the PyroMark PCR kit prior to analysis on a PyroMark
Q24 according to manufacturer’s instruction (Qiagen).
The primer sequences are summarized in Add-
itional file 4: Table S1. Amplification was carried out as
follows: 95 °C for 15 min, followed by 45 cycles of 95 °C
for 30 s, 56 °C for 30 s, and 72 °C for 30 s, with a final
elongation step at 72 °C for 10 min. Products were veri-
fied via gel electrophoresis prior to pyrosequencing
analysis.
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences software (SPSS) (Version
22.0; SPSS UK Ltd., Chertsey, UK). The results are
expressed as mean ± SD, except where otherwise stated.
For normalization purposes, variables were log trans-
formed before analysis, as appropriate. Differences be-
tween treatment groups for participant characteristics
were assessed using an independent t test for continuous
variables or chi-square for categorical variables. Pyrose-
quencing data and RT-qPCR data were analyzed using
Student’s t test to identify statistical differences between
intervention groups. A p value < 0.05 was considered
significant. Differential methylation analysis was con-
ducted in RnBeads (see above) on a site and region level.
The normalized β values were converted into M values
(M = log2(β/(1-β)) and differential methylation between
samples (placebo vs. treatment) was estimated with hier-
archical linear models using limma. Ranking was auto-
matically carried out in RnBeads and was based on the
combination of the average difference in means across
all sites in the promoter regions of the sample groups,
the mean of quotients in mean methylation, and the
combined p value, which was calculated from all site p
values in the region using a generalization of Fisher’s
method [72]. The smaller the combined rank for a re-
gion, the more evidence for differential methylation it
exhibits.
Additional files
Additional file 1: Figure S1. Correlation between folate levels in cord
blood and mother. Scatterplot shows log-converted red blood cell folate
(RCF) levels in nanomoles per liter (nmol/l) at gestational week 36 (GW36)
for mothers (post-intervention) and matched cord blood. The line of best
fit shows significant correlation between mothers and offspring (r = 0.619;
p = < 0.001). (PDF 460 kb)
Additional file 2: Figure S2. QQ plot shows no evidence of population
substructure effects. The observed Chi-squared (χ2) values (open circles),
plotted as –log10 of the p value for both sample groups, fit tightly to the
expected χ2 values (red line), indicating little evidence of association due
to population substructure effects and that the top hits which deviate
from the line (right-hand side) are likely to represent true differences due
to loci with large effects. (PDF 332 kb)
Additional file 3: Figure S3. Median methylation levels at imprint
control regions. Methylation levels at imprint control regions (ICR) were
assessed by matching EPIC array probes to the imprint germline DMR
intervals defined by [48] (A) or [49] (B) then taking the average (median)
across each. The identities of each ICR and number of probes are indicated
below. Boxes show the median and interquartile range for the individual
averages from each group (Placebo n = 45, Treated n = 41), whiskers
represent the range of values, dots indicate outliers. (PDF 1518 kb)
Additional file 4: Table S1. Pyrosequencing and transcriptional primer
sets used in this study. Pyroassay primers are given as bisulfite converted
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sequence. The same primers were used for both RT-PCR and RT-qPCR.
(DOCX 15 kb)
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